A rapidly evolving multi-drug resistant lineage of P. falciparum malaria parasites continues to spread in South East Asia, leading to alarmingly high treatment failure rates in Cambodia, Thailand and Vietnam for DHA-piperaquine, one of the world’s most important anti-malaria drugs.
DHA-piperaquine should no longer be used to treat falciparum malaria in Cambodia, Vietnam and northeast Thailand as it is ineffective and thereby contributes to increased malaria transmission, according to University of Oxford researchers in a study published in The Lancet Infectious Diseases.
The researchers called for urgent action to eliminate falciparum malaria from the Greater Mekong Subregion to prevent local increase of these multiple resistant strains and their further spread to other parts of Asia and Africa and avoid a potential global health emergency.
‘Resistance to our antimalarial drugs is worsening and spreading in the eastern Greater Mekong Subregion,’ said study co-author University of Oxford Professor Sir Nick White. ‘We need urgently to eliminate malaria in this region and act now to prevent the spread of these multi-drug resistant parasites to other parts of Asia and Sub-Saharan Africa. When resistance to previous antimalarial drugs arose in Southeast Asia and spread to Africa-millions of children died as a consequence.’
Malaria deaths dropped significantly after the introduction in the late 1990s of artemisinin-combination therapy (ACT) – where artemisinin, our most effective drug against malaria – is combined with another anti-malaria drug such as piperaquine.
However, in 2014, the Tracking Resistance to Artemisinin Collaboration (TRAC) study reported in the New England Journal of Medicine (NEJM) that artemisinin resistance in P. falciparum– the most deadly form of malaria-causing parasite and the one most prevalent in Africa and Asia – was widespread across the Greater Mekong Subregion.
Since then, global progress against malaria has stalled. Indeed case numbers globally have risen steadily for the past three years, with an estimated 219 million malaria cases (up from 217m in 2016) and 435,000 related deaths in 2017, most of them children under the age of 5 five in sub-Saharan Africa, according to the WHO World Malaria Report 2018.
‘DHA-piperaquine is failing and should no longer be used to treat falciparum malaria across the eastern Greater Mekong Subregion. It provides ineffective treatment for the patient and thereby contributes to increased malaria transmission. This has immediate public health importance, so we felt we should not wait to report this until we published our full TRAC II results later this year,’ said University of Oxford Professor Arjen Dondorp, study co-author and Deputy Director of the Bangkok-based Mahidol Oxford Tropical Medicine Research Unit (MORU).
DHA-piperaquine is an oral artemisinin combination treatment (ACT) medication that is on the WHO’s List of Essential Medicines. DHA-piperaquine is used to treat P. falciparum and P. vivax malaria in Africa and Asia and in large-scale pilot programmes to eliminate malaria in the Greater Mekong Subregion.
Although there are as yet no reports of artemisinin resistance in Africa, researchers urge elimination of these highly drug-resistant P. falciparum parasites in Southeast Asia to preserve the effectiveness of DHA-piperaquine and other ACTs in Africa and elsewhere in Asia and so prevent a global health emergency.
‘Southeast Asia is the cradle of antimalarial drug resistance. We must eliminate falciparum malaria before it becomes untreatable in the Greater Mekong Subregion and elsewhere in Asia. This is the third time that the P. falciparum parasite has developed resistance on a large scale to antimalarial drugs: First, chloroquine and sulphadoxine-pyrimethamine arose and spread in the 60s and 70s, and now resistance has emerged to artemisinin and ACT partner drugs. We must get rid of these parasites once and for all,’ said study co-author Dr Rob van der Pluijm, TRAC II coordinator.
In a companion paper in The Lancet Infectious Diseases, Wellcome Sanger Institute researchers report that the strain of P. falciparum malaria which has become DHA-piperaquine resistant, which they call KEL1/PLA1, has evolved and spread widely in recent years after it was first found in Cambodia. The parasites have acquired new mutations and have produced an even higher level of resistance, allowing their proliferation and spread across the Greater Mekong Subregion.
‘Genetic surveillance data shows that resistant P. falciparum parasites are evolving further, developing new mutations that make them fitter and more resistant, and enabling them to spread regionally, and take over entire parasite populations,’ said University of Oxford Professor Olivo Miotto, study co-author and Senior Informatics Fellow at MORU. ‘We must act quickly to stop the situation getting worse.’
The full paper, ‘Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study,’ can be read in The Lancet Infectious Diseases.
The commentary, ‘Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia.Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia,’ can be read in The Lancet Infectious Diseases.
Source: University of Oxford